Pfizer and Merck have announced that they have submitted three marketing applications for new therapies designed to treat patients diagnosed with type 2 diabetes.
The pharmaceutical giants revealed this week that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both accepted these applications for review, with each treatment containing ertugliflozin, which has shown promise in controlling symptoms for diabetic patients.
“Pfizer and Merck have three marketing applications under review from both the FDA and the EMA.“
The first of the marketing applications concerns a monotherapy, the second is for a fixed-dose combination of the drug along with JANUVIA (sitagliptin) and the third is for ertugliflozin to be administered in conjunction with metformin.
Sam Engel, associate vice-president of clinical research in the field of diabetes and endocrinology at Merck, commented: "The acceptance of the three applications by both the FDA and EMA represents an important milestone in the progression of our collaboration with Pfizer on ertugliflozin."
He added that it also reflects Merck's ongoing commitment to developing new treatments for the growing cohort of patients with type 2 diabetes.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
Image: simonkr via iStockSee all the latest jobs in Pharmaceutical